Gynecologic Cancer | Norton Healthcare

Indication: Gynecologic Cancer

PHASE III TRIAL OF EVERY-3-WEEKS PACLITAXEL VERSUS DOSE DENSE WEEKLY PACLITAXEL IN COMBINATION WITH CARBOPLATIN WITH OR WITHOUT CONCURRENT AND CONSOLIDATION BEVACIZUMAB (NSC #704865, IND #7921) IN THE TREATMENT OF PRIMARY STAGE II, III OR IV EPITHELIAL OVARIAN, PERITONEAL OR FALLOPIAN TUBE CANCER AND ACRIN 6695: PERFUSION CT IMAGING TO EVALUATE TREATMENT RESPONSE IN PATIENTS PARTICIPATING IN GOG-0262.

Sub-indication: Gynecologic Cancer

Drug Study

Principal Investigator: Mary Gordinier, M.D.
Norton Cancer Institute

Sponsor: Gynecologic Oncology Group (GOG)

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.